Echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) is a valid therapeutic target for the treatment of EML4–ALK-positive non-small cell lung cancer (NSCLC). We discovered 12c as a novel and potent EML4–ALK inhibitor through structural optimization of 5a. In mice xenografted with 3T3 cells expressing EML4–ALK, oral administration of 12c demonstrated potent antitumor activity. This article describes the synthesis and biological evaluation of pyrazine-2-carboxamide derivatives along with studies of their structure–activity relationship (SAR) using computational modeling. READ ARTICLE
Bioorganic & Medicinal Chemistry DOI:10.1016/j.bmc.2019.03.018
Authors: Kazuhiko Iikubo, Kazuo Kurosawa,Takahiro Matsuya, Yutaka Kondoh, Akio Kamikawa, Ayako Moritomo, Yoshinori Iwai, Hiroshi Tomiyama, ItsuroShimada